B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Report Overview
The total market value for the 15M, which includes both cell therapies and established/traditional NHL therapies was $16.1 billion in 2021. The market growth will be attributed to the Kymriah, Yescarta, Breyanzi, and Carteyva, which will receive label expansions into earlier lines of therapy and new NHL subtypes.
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Outlook, 2021-2031 ($ Billion)
Buy the Full Report to Know More about the B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Forecast
The B-Cell NHL cell therapy market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.
Market Size (2021) | $16.1 billion |
Forecast Period | 2021-2031 |
Key Regions | · APAC
· Europe · Middle East · North America |
Leading Players | · Allogene Therapeutics
· Artiva Biotherapeutics · Miltenyi Biomedicine · 2Seventy Bio · Fate Therapeutics |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Dynamics
The first-line setting is well-served by chemotherapy plus Rituxan/generic rituximab, with more than half of high-grade NHL patients entering long-term remission. However, ineligibility for intensive therapy and stem cell rescue as well as an inadequate number of long-term remissions, creates a high level of unmet need thereby driving the B-Cell NHL cell therapy market growth.
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Analysis by Treatment
NHL presents several unmet needs that may be addressed by cell therapies. The first line for all NHL populations is well served by chemotherapy, mAb-based therapies, and small molecule inhibitors. The unmet need is largely in the R/R setting where there are limited treatment options for many patients, particularly those who are not candidates for stem cell transplants.
The four marketed CAR-Ts have already addressed a few of the unmet needs but some patients relapse after CAR-T therapy and require further treatment options. Autologous CAR-Ts are also prohibitively expensive and require personalized manufacture.
Buy the Full Report for More Insights into the B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Treatment
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Segmentation by Regions
North America had the highest sales in 15MM in the B-Cell NHL cell therapy market.
A few of the key regions in the market are APAC, Europe, Middle East, and North America.
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Analysis by Regions, 2021 (%)
Buy the Full Report for More Regional Insights into the B-Cell Non-Hodgkins Lymphoma Cell Therapy Market
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market - Competitive Landscape
Novartis, Kite Pharma, and Gilead are the leading sponsors of cell therapy trials in NHL. Moreover, the majority of Phase III trials are label expansions of already marketed CAR-Ts.
A few of the major players in the B-Cell Non-Hodgkins Lymphoma cell therapy market are:
- Allogene Therapeutics
- Artiva Biotherapeutics
- Miltenyi Biomedicine
- 2Seventy Bio
- Fate Therapeutics
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Analysis by Companies
Buy the Full Report to Know More about Companies in the B-Cell Non-Hodgkins Lymphoma Cell Therapy Market, Download A Free Report Sample
B-Cell Non-Hodgkins Lymphoma Cell Therapy Country Outlook (Value, $ Billion, 2021-2031)
- APAC
- Europe
- Middle East
- North America
Reasons to Buy
The report will help you to understand:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication?
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Gilead
JW Therapeutics
Merck & Co
Novartis
Allogene Therapeutics
Caribou Biosciences
Fate Therapeutics
2SEventyBio
Table of Contents
Frequently asked questions
-
What are the key regions in the B-cell NHL market?
The key regions in the B-cell NHL market are North America, APAC, Europe, and the Middle East.
-
What was the B-Cell NHL cell therapy market size across the 15M in 2021?
The B-Cell NHL cell therapy market size across the 15M was valued at $16.1 billion in 2021.
-
Which region had the highest sales in the 8MM B-Cell NHL cell therapy market?
North America held the highest sales in the B-Cell NHL cell therapy market across the 8MM in 2021.
-
Who are the leading players operating in the B-Cell NHL cell therapy market?
A few of the major players in the B-Cell NHL cell therapy market are Allogene Therapeutics, Artiva Biotherapeutics, Miltenyi Biomedicine, 2Seventy Bio, and Fate Therapeutics among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.